Located in West Haven, Connecticut, NanoVircides is a development stage company that is creating special purpose nanomaterials for viral therapy. Yesterday, the young company announced they have had their novel, proprietary anti-virus platform technology published in the book “Bioanotechnology II: Global Prospects.”
The chapter, titled “Nanoviridies-A Novel Approach to Antiviral Therapeutics,” provides an in-depth presentation of the NanoVircides platform technology and displays how the technology is having a profound effect on HIV and an array of other deadly diseases.
In a statement about the chapter contributed by NanoViricides, the publisher stated, “The impact and importance of nanotechnology continues to grow, and nanomedicine and biotechnology have become areas of increased development. Bionanotechnology II: Global Prospects, David Reisner Editor, a follow-up to the editor’s highly successful first volume, contains 26 entirely new contributions that provide a broad survey of research shaping this critical field. With coverage of technical and non-technical areas, the book reports on a wide variety of activity from around the world. It discusses the role of nanotechnology in novel medical devices, bioanalytical technologies, and nanobiomaterials”.
This honor has established NanoViricides as a leader within their sector and may be a sign of bigger things to come. Currently, the young company is trading in the $0.86 range. To learn more about the company as a whole, visit their corporate website at: www.nanoviricides.com
Let us hear your thoughts below:
